A Phase 2a Study to Evaluate the Pharmacokinetic, Safety, Tolerability and Clinical Effect of Topically Applied Umeclidinium/GSK573719 in Subjects With Primary Axillary Hyperhidrosis
Phase of Trial: Phase II
Latest Information Update: 21 Nov 2017
At a glance
- Drugs Umeclidinium (Primary)
- Indications Hyperhidrosis
- Focus Adverse reactions; Pharmacokinetics
- Sponsors GlaxoSmithKline
- 10 Mar 2016 Status changed from recruiting to completed, according to ClinicalTrials.gov record.
- 05 Jan 2016 Planned end date changed from 1 Mar 2016 to 1 May 2016, as reported by ClinicalTrials.gov.
- 05 Jan 2016 Planned primary completion date changed from 1 Mar 2016 to 1 May 2016, as reported by ClinicalTrials.gov.